A critical narrative review published in Cellular and Molecular Neurobiology examines the cell-type- and isoform-specific roles of fatty acid-binding proteins in Alzheimer’s disease, evaluating distinctions among human associations, perturbation studies in disease models, and mechanisms inferred from other experimental settings. While brain lipid dysregulation accompanies Alzheimer’s disease, the authors note that the specific contribution of individual lipid-handling proteins to overall disease progression remains uncertain.

Fatty acid-binding proteins, or FABPs, link intracellular fatty-acid trafficking to downstream signaling pathways and vary significantly in their cellular distribution and ligand interactions. In clinical investigations, fatty acid-binding protein 3 measured in cerebrospinal fluid is associated with amyloid burden, regional brain atrophy, and cognitive decline. However, the review emphasizes that the disease specificity of FABP3 and its added diagnostic value in clinical practice remain uncertain.

The review also evaluates endothelial fatty acid-binding protein 5, which supports docosahexaenoic acid handling within experimental laboratory systems. Despite this physiological role in lipid transport, researchers report that empirical evidence demonstrating that selectively increasing FABP5 activity modifies Alzheimer’s disease pathology or outcomes is currently lacking.

In the brain parenchyma, fatty acid-binding protein 7 abundance increases in plaque-associated astrocytes, and genetic overexpression experiments implicate its ligand binding in inflammatory signaling cascades. Nevertheless, whether endogenous FABP7 directly drives astrocyte dysfunction in human Alzheimer’s disease remains unknown. Conversely, neuronal perturbation of fabp in Drosophila supports a protective role in amyloid-related phenotypes, though these fruit fly findings leave the specific functions of individual mammalian isoforms unresolved.

Hypothesized mechanisms such as an arachidonic-acid to docosahexaenoic-acid switch and apolipoprotein E-dependent regulation of FABP7 provide testable pathways but do not yet offer a foundation for therapeutic treatment. To guide future research, the authors propose an evidence-to-action framework setting distinct priorities: incremental biomarker validation for FABP3, selective neurovascular perturbation for FABP5, and cell- and ligand-resolved experimental studies for FABP7. Successful clinical translation will ultimately require distinguishing secondary biological changes that accompany tissue injury from functional mechanisms that can be modified to improve disease-relevant outcomes.

Subject of Research: Roles of fatty acid-binding proteins in Alzheimer's disease

Article Title: Cell-Type-and Isoform-Specific Roles of Fatty Acid-Binding Proteins in Alzheimer’s Disease: An Evidence-to-Action Framework

Article References: Li, J., Shi, X., Huo, Y., Liu, L., & Wang, F. (2026). Cell-Type-and Isoform-Specific Roles of Fatty Acid-Binding Proteins in Alzheimer’s Disease: An Evidence-to-Action Framework. Cellular and Molecular Neurobiology. https://doi.org/10.1007/s10571-026-01826-3

Image Credits: AI Generated

DOI: 10.1007/s10571-026-01826-3

Keywords: Alzheimer's disease, fatty acid-binding proteins, FABP3, FABP5, FABP7, neurobiology, lipid metabolism, biomarkers, Cell-Type-and, Isoform-Specific, Roles, Fatty